Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cilia and flagella associated protein 300 (CFAP300) is a cytoplasmic protein critical for the proper assembly of outer and inner dynein arms in motile cilia and flagella, thus enabling normal axonemal structure and movement. Mutations in CFAP300 cause defects in ciliary and flagellar function, resulting in primary ciliary dyskinesia (PCD), a genetically heterogeneous disorder characterized by impaired mucociliary clearance, chronic respiratory tract disease, and male infertility due to sperm flagellar defects. The protein is not currently considered a direct therapeutic target; rather, it is most relevant as a diagnostic marker and in genetic counseling for ciliary disorders[1][2][3][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cilia and flagella associated protein 300 (CFAP300).